NO923509L - N-substituerte heterocykliske forbindelser, fremstilling derav og farmasoeytiske blandinger som inneholder dem - Google Patents

N-substituerte heterocykliske forbindelser, fremstilling derav og farmasoeytiske blandinger som inneholder dem

Info

Publication number
NO923509L
NO923509L NO92923509A NO923509A NO923509L NO 923509 L NO923509 L NO 923509L NO 92923509 A NO92923509 A NO 92923509A NO 923509 A NO923509 A NO 923509A NO 923509 L NO923509 L NO 923509L
Authority
NO
Norway
Prior art keywords
preparing
substituted heterocyclic
heterocyclic compounds
mixtures containing
pharmaceutical mixtures
Prior art date
Application number
NO92923509A
Other languages
English (en)
Other versions
NO180678B (no
NO923509D0 (no
NO180678C (no
Inventor
Pierre Perreaut
Claude Muneaux
Yvette Muneaux
Original Assignee
Sanofi Elf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Elf filed Critical Sanofi Elf
Publication of NO923509D0 publication Critical patent/NO923509D0/no
Publication of NO923509L publication Critical patent/NO923509L/no
Publication of NO180678B publication Critical patent/NO180678B/no
Publication of NO180678C publication Critical patent/NO180678C/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/70One oxygen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84Sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO923509A 1991-09-10 1992-09-09 N-substituerte heterocykliske forbindelser og farmasöytisk preparat NO180678C (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9111161A FR2681067B1 (fr) 1991-09-10 1991-09-10 Derives heterocycliques n-substitues, leur preparation, les compositions pharmaceutiques en contenant.

Publications (4)

Publication Number Publication Date
NO923509D0 NO923509D0 (no) 1992-09-09
NO923509L true NO923509L (no) 1993-03-11
NO180678B NO180678B (no) 1997-02-17
NO180678C NO180678C (no) 1997-05-28

Family

ID=9416798

Family Applications (1)

Application Number Title Priority Date Filing Date
NO923509A NO180678C (no) 1991-09-10 1992-09-09 N-substituerte heterocykliske forbindelser og farmasöytisk preparat

Country Status (19)

Country Link
EP (1) EP0532410A1 (no)
JP (1) JPH05213894A (no)
KR (1) KR930006008A (no)
AU (1) AU661017B2 (no)
CA (1) CA2077967A1 (no)
CZ (1) CZ275992A3 (no)
FR (1) FR2681067B1 (no)
HU (1) HUT63616A (no)
IL (1) IL103116A (no)
LT (1) LT3148B (no)
LV (1) LV10255B (no)
MX (1) MX9205155A (no)
MY (1) MY108089A (no)
NO (1) NO180678C (no)
NZ (1) NZ244258A (no)
PL (1) PL171524B1 (no)
RU (1) RU2107062C1 (no)
TW (1) TW218871B (no)
ZA (1) ZA926899B (no)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100222252B1 (ko) * 1990-12-14 1999-10-01 스튜어트 알. 수터 안지오텐신 ii 수용체 차단 조성물
US5484939A (en) * 1993-03-12 1996-01-16 Lonza Ltd. 2-substituted 5-chlorimidazoles
US5721263A (en) * 1993-06-07 1998-02-24 Takeda Chemical Industries, Ltd. Pharmaceutical composition for angiotensin II-mediated diseases
HU218681B (hu) * 1997-07-25 2000-10-30 Sanofi-Synthelabo Eljárás 1,3-diaza-spiro(4,4)non-1-én-4-on-származékok előállitására és 1-ciano-1-(acil-amino)-ciklopentán intermedierek
HU218680B (hu) 1997-07-25 2000-10-30 Sanofi-Synthelabo Eljárás 1,3-diaza-spiro[4,4]non-1-én-4-on-származékok előállítására és 1-ciano-1-(acil-amino)-ciklopentán intermedierek
US6638937B2 (en) 1998-07-06 2003-10-28 Bristol-Myers Squibb Co. Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
HUP0104634A3 (en) 1998-07-06 2002-11-28 Bristol Myers Squibb Co Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
DE19832428A1 (de) * 1998-07-18 2000-01-20 Hoechst Marion Roussel De Gmbh Imidazolderivate mit Biphenylsulfonylsubstitution, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE19832429A1 (de) * 1998-07-18 2000-01-20 Hoechst Marion Roussel De Gmbh Imidazolderivate mit Biphenylsulfonylsubstitution, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
US7091232B2 (en) * 2002-05-21 2006-08-15 Allergan, Inc. 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
KR20120058618A (ko) 2003-01-31 2012-06-07 다이이찌 산쿄 가부시키가이샤 동맥 경화 및 고혈압증의 예방 및 치료를 위한 의약
DE602005025755D1 (de) 2004-06-04 2011-02-17 Teva Pharma Irbesartan enthaltende pharmazeutische zusammensetzung
BRPI0609879A2 (pt) * 2005-04-28 2010-05-11 Pfizer Ltd derivados de aminoácidos
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
MX354786B (es) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
ES2522968T3 (es) 2008-06-04 2014-11-19 Synergy Pharmaceuticals Inc. Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
AU2009270833B2 (en) 2008-07-16 2015-02-19 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
AU2014235215A1 (en) 2013-03-15 2015-10-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
AU2014235209B2 (en) 2013-03-15 2018-06-14 Bausch Health Ireland Limited Guanylate cyclase receptor agonists combined with other drugs
BR112015030326A2 (pt) 2013-06-05 2017-08-29 Synergy Pharmaceuticals Inc Agonistas ultrapuros de guanilato ciclase c, método de fabricar e usar os mesmos

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH539640A (de) 1970-05-29 1973-07-31 Agripat Sa Verfahren zur Herstellung neuer, herbizid wirksamer s-Triazine und deren Verwendung zur Bekämpfung von Unkräutern
US4017510A (en) 1975-11-12 1977-04-12 American Cyanamid Company Imidazoisoindolediones and the use thereof as herbicidal agents
DE3545597A1 (de) * 1985-12-21 1987-07-02 Celamerck Gmbh & Co Kg Neue herbizid wirksame imidazolinone
EP0303863A3 (en) * 1987-08-17 1991-10-23 American Cyanamid Company Benzenesulfonyl carboxamide compounds, intermediate compounds and methods of preparation thereof and use of said compounds and intermediate compounds as herbicidal agents
US4880804A (en) * 1988-01-07 1989-11-14 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking benzimidazoles
CA2020073A1 (en) * 1989-07-03 1991-01-04 Eric E. Allen Substituted quinazolinones as angiotensin ii antagonists
EP0412594B1 (en) * 1989-07-28 1996-01-03 Merck & Co. Inc. Substituted triazolinones, triazolinethiones, and triazolinimines as angiotensin II antagonists
IL99372A0 (en) * 1990-09-10 1992-08-18 Ciba Geigy Ag Azacyclic compounds
JP2004247578A (ja) 2003-02-14 2004-09-02 Kawasaki Microelectronics Kk 半導体装置および半導体装置の製造方法

Also Published As

Publication number Publication date
AU2286892A (en) 1993-03-11
MX9205155A (es) 1993-03-01
RU2107062C1 (ru) 1998-03-20
LV10255B (en) 1995-04-20
LTIP119A (en) 1994-07-15
PL171524B1 (pl) 1997-05-30
IL103116A0 (en) 1993-02-21
LT3148B (en) 1995-01-31
HUT63616A (en) 1993-09-28
NO180678B (no) 1997-02-17
PL295874A1 (en) 1993-04-19
AU661017B2 (en) 1995-07-13
TW218871B (no) 1994-01-11
MY108089A (en) 1996-08-15
FR2681067A1 (fr) 1993-03-12
IL103116A (en) 1998-04-05
FR2681067B1 (fr) 1993-12-17
LV10255A (lv) 1994-10-20
NZ244258A (en) 1996-10-28
JPH05213894A (ja) 1993-08-24
CA2077967A1 (en) 1993-03-11
NO923509D0 (no) 1992-09-09
HU9202889D0 (en) 1992-11-30
NO180678C (no) 1997-05-28
EP0532410A1 (fr) 1993-03-17
KR930006008A (ko) 1993-04-20
CZ275992A3 (en) 1993-03-17
ZA926899B (en) 1993-03-16

Similar Documents

Publication Publication Date Title
NO922940D0 (no) Fem-leddete heterocykliske forbindelser, fremgangsmaate for deres fremstilling og legemidler inneholdende dem
NO923509L (no) N-substituerte heterocykliske forbindelser, fremstilling derav og farmasoeytiske blandinger som inneholder dem
DK0835246T3 (da) Aromatiske forbindelser og farmaceutiske præparater, der indeholder dem
DK0612741T3 (da) Cykliske derivater, lægemidler indeholdende disse forbindelser og fremgangsmåde til deres fremstilling
DK0477049T3 (da) 3-amido-pyrazolderivater, fremgangsmåde til deres fremstilling og farmaceutiske præparater indeholdende dem
NO304374B1 (no) 1-benzensulfonyl-1,3-dihydro-2H-benzimidazol-2-on-derivater, og farmas°ytiske blandinger som inneholder dem
DK0567966T3 (da) Cykliske aminoderivater, fremgangsmåder til deres fremstilling og lægemidler indeholdende disse forbindelser
NO924027D0 (no) Heterobiarylderivater, legemidler inneholdende disse forbindelser, og fremgangsmaate for deres fremstilling
DK0502314T3 (da) Benzimidazoler, lægemidler indeholdende disse forbindelser og fremgangsmåder til deres fremstilling
NO932120D0 (no) Bifenylderivater, legemidler inneholdende disse, og fremgangsmaate for deres fremstilling
DK605989A (da) Propenonoximethere og fremgangsmaade til fremstilling deraf samt farmaceutiske midler indeholdende dem
DK286190D0 (da) Glycosaminoglycansalte, fremgangsmaader til fremstilling heraf og farmaceutiske midler indeholdende dem
DK162491D0 (da) Heterocycliske forbindelser, deres fremstilling og farmaceutiske praeparater indeholdende forbindelserne
DK0732328T3 (da) Heterocykliske, aromatiske forbindelser, farmaceutiske og kosmetiske sammensætninger, der indeholder dem, og anvendelser
NO932636L (no) Benzimidazoler, medikamenter inneholdende disse forbindelser, og fremgangsmaate for deres fremstilling
DK0946567T3 (da) Hidtil ukendte camptothecinanaloge forbindelser, deres anvendelse som lægemidler og farmaceutiske præparater, der indeholder dem
NO930796D0 (no) Glykopeptidderivater, fremgangsmaate for deres fremstilling og farmasoeytiske midler inneholdende disse
NO166937C (no) Aromatiske naftylderivater for kosmetisk anvendelse og kosmetiske blandinger som inneholder dem.
DK269289D0 (da) Cyklopentanderivater og farmaceutiske praeparater indeholdende saadanne forbindelser
NO933558D0 (no) Benzimidazoler, legemidler inneholdende disse forbindelser, og fremgangsmaate for deres fremstilling
DK187989D0 (da) Substituerede propanaminer, fremgangsmaade til fremstilling heraf og laegemidler indeholdende saadanne forbindelser
DK597184D0 (da) Substituerede spiro-pyridinderivater, farmaceutiske praeparater indeholdende dem og fremgangsmaade til fremstilling af saadanne forbindelser
NO923720D0 (no) Tienocyklopentanonoksimetere, fremstilling derav og farmasoeytiske blandinger som inneholder dem
DK0794184T3 (da) 6-Methoxy-1H-benzotriazol-5-carboxamidderivater, fremgangsmåde til fremstilling deraf og lægemidler indeholdende dem
NO305959B1 (no) Tiosubstituerte cykliske fosfonatforbindelser, anvendelser derav, og farmasoeytiske preparater inneholdende slike forbindelser